x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012940
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Mouse |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human UCP1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | UCP1 |
| UniProt No. | P25874 |
| Gene ID | 7350 |
| Gene Description | Coupling protein 1 is a mitochondrial inner membrane transport protein that is primarily expressed in brown adipose tissue. UCP1 dissipates the pH gradient resulting from oxidative phosphorylation, which uncouples ATP synthesis from oxidative phosphorylation and leads to the release of heat energy. As a result, UCP1 plays an important role in thermogenesis. Research studies indicate that subcutaneous white adipose depots in mice contain beige adipocytes that express low levels of UCP1 protein. Additional studies show possible differences in thermogenesis in individuals carrying specific polymorphisms in the corresponding UCP1 gene. Related studies link UCP1 to the possible development of obesity and type 2 diabetes. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
